Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24012909 | 0.83 | KDM4C (0.42) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL12093775 | 0.79 | KDM4C (0.38) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL9219137 | 0.79 | KDM4C (0.40) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL24123654 | 0.77 | KDM4C (0.42) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL20213510 | 0.77 | KDM4C (0.42) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL28410468 | 0.77 | KDM4C (0.37) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL28847382 | 0.76 | KDM4C (0.39) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL10839336 | 0.76 | KDM4C (0.38) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL26975094 | 0.76 | KDM4C (0.38) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL20519517 | 0.75 | MET (0.44) | KDM4CMEN1KMT2AL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| EP-4146658-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021224320-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, RIN1, GRK3 | KDM4C 2968/4885MEN1 1856/4885KMT2A 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.